Keyword: Elan Biogen

News

Elan Strikes $1 Billion Royalty Deal with Theravance

13.05.2013 - Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21% of the royalties that U.S. company Theravance receives from GlaxoSmithKline for...

News

Elan Board Unanimously Rejects Royalty Pharma Bid

22.04.2013 - The board of Irish drugmaker Elan unanimously rejected a formal bid from Royalty Pharma on Monday, saying the U.S. investment firm's offer of $11.25 a share grossly undervalues the...

News

J&J Stake Sale Clouds Royalty Bid for Elan

19.04.2013 - U.S. healthcare firm Johnson & Johnson cut its stake in Elan on Thursday in a move that clouds prospects for a $7.3 billion takeover bid for the Irish drugmaker. U.S. investment...

News

Royalty Pharma Considers Sweetened Deal for Elan

12.04.2013 - U.S. investment firm Royalty Pharma is considering sweetening its $6.6 billion offer for Irish drugmaker Elan by paying Elan shareholders more if the multiple sclerosis drug...

News

Elan to Start Share Buyback Next Week

10.03.2013 - Drugmaker Elan is to bring forward a planned $1 billion share buyback to next week, the Irish company said in a statement, a move that could undermine a takeover offer by U.S...

News

Royalty Pharma Proposes $6.6 Billion Bid for Elan

25.02.2013 - Investment firm Royalty Pharma has made a $6.6 billion bid approach to Elan, seeking to scupper the Irish drugmaker's plan to spend most of the proceeds from a major drug sale on...